Search Results

You are looking at 11 - 20 of 369 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

Use of Biomarkers in Individualization of Treatment

Presented by: Jennifer J.D. Morrissette

resistance mutations to guide treatment selection. The FDA has a growing list of genomic biomarkers associated with specific drugs in the field of oncology that include targeted therapeutics, contraindications, clinical pharmacology, and clinical studies. NGS

Full access

The Microbiome Colorectal Cancer Puzzle: Initiator, Propagator, and Avenue for Treatment and Research

Reece J. Knippel and Cynthia L. Sears

treatment among cancer types. Establishing a potential core bacterial group that demarcates potential immunotherapy responders or nonresponders is an active area of investigation. Microbial Therapeutics The importance of the microbiome in CRC

Full access

Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms

Brady L. Stein, Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, Daniel A. Pollyea, Bart Scott, Martha Wadleigh, Ross Levine, Rami Komrokji, Rebecca Klisovic, Krishna Gundabolu, Patricia Kropf, Meir Wetzler, Stephen T. Oh, Raul Ribeiro, Rita Paschal, Sanjay Mohan, Nikolai Podoltsev, Josef Prchal, Moshe Talpaz, David Snyder, Srdan Verstovsek, and Ruben A. Mesa

Prognostic Scoring System [IPSS]) 10 or during follow-up (Dynamic IPSS [DIPSS], DIPSS plus; Table 1 ). 11 , 12 As important, the recognition of JAK-STAT dysregulation has led to the identification of novel therapeutics, culminating in the first approval

Full access

BRAFV600E -Mutant Melanoma Presenting With Cardiac Involvement

Douglas B. Johnson and Jeffrey A. Sosman

with 5.8 months for dabrafenib monotherapy ( P <.001). 8 Unfortunately, resistance to these agents inevitably develops and almost all patients experience disease progression within 2 years of therapy initiation. The second major class of therapeutics

Full access

Strategies for Optimizing the Clinical Impact of Immunotherapeutic Agents Such as Sipuleucel-T in Prostate Cancer

Ravi A. Madan, Thomas Schwaab, and James L. Gulley

standard therapeutics. Radiation, ADT, and chemotherapy could all work in concert with therapeutic cancer vaccines via numerous mechanisms to enhance clinical outcomes. 26 Immune-Based Therapies May Be Combined With Standard Therapies for More

Full access

NCCN News

Specialized Imaging Research Consortium (SIRC) aims to advance the treatment of patients with cancer through the clinical application of specialized imaging technologies. This is achieved by performing high-quality clinical trials of emerging therapeutics

Full access

Carcinoma of Unknown Primary: Focused Evaluation

Gauri R. Varadhachary

decade, with the advent of sophisticated imaging and pathologic tests. 1 – 3 Especially in the era of tailored therapeutics, this presents both an opportunity and a challenge. CUP cancers can be approached in two distinct ways, and this may impact

Full access

Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda

significant disease progression, and he was transitioned to best supportive care and died 6 weeks later. Discussion As additional information is learned regarding the molecular mutations that drive oncogenesis, targeted therapeutics have played an

Full access

CGE19-063: Creating a Clinical-Molecular Database to Study Patients with BRAF V600E-Mutated Brain Tumors

Yamini V. Ananth and Karisa Schreck

natural history of different genomic subtypes of glioblastoma is critical for the appropriate application of novel therapeutics. Here we demonstrate that a clinical-pathological database consisting of clinical and molecular data from patients with an

Full access

Defining and Managing High-Risk Multiple Myeloma: Current Concepts

Luciano J. Costa and Saad Z. Usmani

factors in MM, creating the need to revise the ISS in light of cytogenetic data and more modern therapeutics. Figure 1. ISS and R-ISS for multiple myeloma. Abbreviations: FISH, fluorescence in situ hybridization; ISS, International Staging System; LDH